Search Results - "Kennecke, Hagen F"

Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix by Tsang, Erica S., McConnell, Yarrow J., Schaeffer, David F., Lee, Lawrence, Yin, Yaling, Zerhouni, Siham, Schaff, Kimberly, Speers, Caroline, Kennecke, Hagen F.

“…Background Goblet cell carcinoids (GCCs) of the appendix are rare mucinous neoplasms, for which optimal therapy is poorly described. We examined prognostic…”
Get full text

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer by Peixoto, Renata D'Alpino, Speers, Caroline, McGahan, Colleen E., Renouf, Daniel J., Schaeffer, David F., Kennecke, Hagen F.

“…Due to differences in natural history and therapy, clinical trials of patients with advanced pancreatic cancer have recently been subdivided into unresectable…”
Get full text

Association Between Palliative Resection of the Primary Tumor and Overall Survival in a Population-Based Cohort of Metastatic Colorectal Cancer Patients by Gresham, Gillian, Renouf, Daniel J., Chan, Matthew, Kennecke, Hagen F., Lim, Howard J., Brown, Carl, Cheung, Winson Y.

“…Background The impact of palliative resection of the primary tumor on outcomes in patients with metastatic colorectal cancer (mCRC) remains unclear. The…”
Get full text

Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum by Tsang, Erica S, McConnell, Yarrow J, Schaeffer, David F, Yin, Yaling, Speers, Caroline H, Kennecke, Hagen F

“…BACKGROUND:Optimal management of rectal neuroendocrine tumors is not yet well defined. Various pathologic factors, particularly tumor size, have been proposed…”
Get full text

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT by Tsang, Erica S, Funk, Gayle, Leung, Janet, Kalish, Grace, Kennecke, Hagen F

“…Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs). Patients are…”
Get full text

Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases by Kennecke, Hagen F., Lim, Howard J., Ho, Stephen, Liu, David, Gill, Sharlene, Davies, Janine M., Loree, Jonathan M., Tsang, Erica S., Renouf, Daniel J.

“…Background. Yttrium-90 (Y-90) can be an effective liver-directed therapy for patients with metastatic neuroendocrine tumors (NETs), but population-based data…”
Get full text

Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53‐mediated cellular senescence by Wong, John C.T., Hasan, Mohammad R., Rahman, Mahbuba, Yu, Angel C., Chan, Simon K., Schaeffer, David F., Kennecke, Hagen F., Lim, Howard J., Owen, David, Tai, Isabella T.

“…Dysregulation of nucleophosmin 1 (NPM1) has been found in numerous solid and hematological malignancies. Our previous meta‐analysis of colorectal cancer (CRC)…”
Get full text

Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer by Boutin, Mélina, Topham, James T., Feilotter, Harriet, Kennecke, Hagen F., Couture, Félix, Harb, Mohammed, Kavan, Peter, Berry, Scott, Lim, Howard J., Goffin, John R., Ahmad, Chaudhary, Lott, Anthony, Renouf, Daniel J., Jonker, Derek J., Tu, Dongsheng, O’Callaghan, Chris J., Chen, Eric X., Loree, Jonathan M.

“…Background: The number of somatic mutations detectable in circulating tumor DNA (ctDNA) is highly heterogeneous in metastatic colorectal cancer (mCRC). The…”
Get full text

Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer by Dascalu, Bogdan, Kennecke, Hagen F., Lim, Howard J., Renouf, Daniel J., Ruan, Jenny Y., Chang, Jennifer T., Cheung, Winson Y.

“…Purpose There are concerns regarding potential negative effects of prophylactic treatment of epidermal growth factor receptor (EGFR)-inhibitor-related rashes…”
Get full text

Impact of Routine Pathology Review on Treatment for Node-Negative Breast Cancer by KENNECKE, Hagen F, SPEERS, Caroline H, ENNIS, Catherine A, GELMON, Karen, OLIVOTTO, Ivo A, HAYES, Malcolm

“…Routine secondary pathology review influences diagnosis and treatment among patients diagnosed with breast cancer. The impact of review on patients with…”
Get full text

Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy by Loree, Jonathan M., Kennecke, Hagen F., Renouf, Daniel J., Lim, Howard J., Vickers, Michael M., Speers, Caroline H., Cheung, Winson Y.

“…The benefit of adjuvant chemotherapy for rectal cancer is controversial, and recent studies have focused on the outcomes after chemoradiotherapy. In the…”
Get full text

A comparison of survival by site of metastatic resection (MR) in metastatic colorectal cancer (mCRC) by Lee-Ying, Richard, MD, Bernard, Brandon, MD, Gresham, Gillian, Chen, Leo, Speers, Caroline, Kennecke, Hagen F., MD, Lim, Howard John, MD PhD, Cheung, Winson Y., MD MPH, Renouf, Daniel John, MD MPH

“…Abstract Background Metastatic resection (MR) of liver-limited disease is an effective therapy for selected patients with metastatic colorectal cancer (mCRC)…”
Get full text

Preoperative Treatment of Locally Advanced Rectal Cancer by Schrag, Deborah, Shi, Qian, Weiser, Martin R., Gollub, Marc J., Saltz, Leonard B., Musher, Benjamin L., Goldberg, Joel, Al Baghdadi, Tareq, Goodman, Karyn A., McWilliams, Robert R., Farma, Jeffrey M., George, Thomas J., Kennecke, Hagen F., Shergill, Ardaman, Montemurro, Michael, Nelson, Garth D., Colgrove, Brian, Gordon, Vallerie, Venook, Alan P., O’Reilly, Eileen M., Meyerhardt, Jeffrey A., Dueck, Amylou C., Basch, Ethan, Chang, George J., Mamon, Harvey J.

“…In a trial comparing preoperative chemoradiotherapy and FOLFOX in patients with rectal cancer undergoing sphincter-sparing surgery, 5-year disease-free…”
Get full text

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases by Loree, Jonathan M., Hiruki, Tadaaki, Kennecke, Hagen F.

“…Background: Management options for pancreatic neuroendocrine tumors (pNETs) metastatic to the liver include surgical, ablative, cytotoxic, and radioisotope…”
Get full text

Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer by Kumar, Aalok, Kennecke, Hagen F., Renouf, Daniel J., Lim, Howard J., Gill, Sharlene, Woods, Ryan, Speers, Caroline, Cheung, Winson Y.

“…BACKGROUND Adjuvant chemotherapy (AC) is frequently considered in patients with stage II colon cancer who are considered to be at high risk. However, to the…”
Get full text

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study by Chen, Eric X, Jonker, Derek J, Loree, Jonathan M, Kennecke, Hagen F, Berry, Scott R, Couture, Felix, Ahmad, Chaudhary E, Goffin, John R, Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L, Wei, Alice C, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Chris J

“…Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are…”
Get more information

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer by Topham, James T, O'Callaghan, Chris J, Feilotter, Harriet, Kennecke, Hagen F, Lee, Young S, Li, Weimin, Banks, Kimberly C, Quinn, Katie, Renouf, Daniel J, Jonker, Derek J, Tu, Dongsheng, Chen, Eric X, Loree, Jonathan M

“…Anti-epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired…”
Get full text

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results by Kennecke, Hagen F, O'Callaghan, Chris J, Loree, Jonathan M, Moloo, Hussein, Auer, Rebecca, Jonker, Derek J, Raval, Manoj, Musselman, Reilly, Ma, Grace, Caycedo-Marulanda, Antonio, Simianu, Vlad V, Patel, Sunil, Pitre, Lacey D, Helewa, Ramzi, Gordon, Vallerie L, Neumann, Katerina, Nimeiri, Halla, Sherry, Max, Tu, Dongsheng, Brown, Carl J

“…Organ-sparing therapy for early-stage I/IIA rectal cancer is intended to avoid functional disturbances or a permanent ostomy associated with total mesorectal…”
Get full text

The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2α and IRE1α/XBP-1 in colorectal cancer by Chern, Yi-Jye, Wong, John C. T., Cheng, Grace S. W., Yu, Angel, Yin, Yaling, Schaeffer, David F., Kennecke, Hagen F., Morin, Gregg, Tai, Isabella T.

“…Therapy-refractory disease is one of the main contributors of treatment failure in cancer. In colorectal cancer (CRC), SPARC can function as a sensitizer to…”
Get full text

The utility of abbreviated patient‐reported outcomes for predicting survival in early stage colorectal cancer by Hsu, Tina, Speers, Caroline H., Kennecke, Hagen F., Cheung, Winson Y.

“…BACKGROUND Patient‐reported outcomes (PROs) are increasingly used in clinical settings. Prior research suggests that PROs collected at baseline may be…”
Get full text